David Gardner

Försäljning & Marknadsföring på

iShares Plc

Finance

Miscellaneous

Health Technology

Profil

David Gardner is currently the Head-EMEA Sales at iShares Plc.
Prior to this, he worked as a Director at Xilio Therapeutics, Inc. in 2021.
He also worked as an Analyst at BlackRock Advisors LLC from 2009 to 2011.

Aktiva positioner av David Gardner

Företag	Position	Start
iShares Plc iShares Plc Investment Trusts/Mutual FundsMiscellaneous Exchange Traded Fund	Försäljning & Marknadsföring	2011-10-20

Alla aktiva positioner av David Gardner

Tidigare kända positioner av David Gardner

Företag	Position	Slut
XILIO THERAPEUTICS, INC.	Direktör/Styrelseledamot	2021-10-01
BlackRock Advisors LLC BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors offers investors around the world a variety of investment products that span across asset classes, market-caps, investment styles and geographic regions. Their mandates include cash management, equity, fixed income, alternative, multi-asset and quantitative equity strategies.	Analyst-Equity	2011-09-09

Se detaljerna i David Gardners erfarenhet

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Se detaljerna i David Gardners erfarenhet

Relationer

Första gradens relationer

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Se det personliga nätverket

Kopplade företag

Privata företag	3
BlackRock Advisors LLC BlackRock Advisors LLC Investment ManagersFinance BlackRock Advisors offers investors around the world a variety of investment products that span across asset classes, market-caps, investment styles and geographic regions. Their mandates include cash management, equity, fixed income, alternative, multi-asset and quantitative equity strategies.	Finance
iShares Plc iShares Plc Investment Trusts/Mutual FundsMiscellaneous Exchange Traded Fund	Miscellaneous
Xilio Therapeutics, Inc. Xilio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops tumor-selective immuno-oncology therapies	Health Technology